Valiant Laboratories share price & results
- Jun 2026
- Sept 2026
Paracetamol API manufacturer running a single Tarapur (Maharashtra) plant, part of the Aarti Group, diversifying into specialty chemicals via subsidiary VASPL.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 73.4 | +43.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 17.0 | +12.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 9.5 | +420.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 5.87 | −0.5 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -18.57 | +66.4 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 89.44 | +105.1 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance +42.0% 1Y
1Y: ₹86.86 on 24 Oct 2025 → ₹123.36. High ₹140.75 (19 Oct 2026), low ₹50.93 (18 Mar 2026).
- Previous close
- ₹125.87
- Market cap
- ₹684 Cr
- 52-week range
- ₹50.93 – ₹140.75
- One year
- +44.11%
- Price to earnings (TTM to Jun 2026)
- 42.75×
- Return on equity (TTM to Jun 2026)
- 5.87%
Overview
- Symbol
- NSE:VALIANTLAB
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Valiant Laboratories Limited does
Based on the company's own presentations, annual report and earnings calls.
Valiant Laboratories Limited manufactures Active Pharmaceutical Ingredients (APIs), with its core business built around Paracetamol API produced in Powder, Fine Powder and Crystals grades meeting IP/BP/USP/EP pharmacopoeia standards. It sells to pharmaceutical companies that use the API to make tablets, capsules and other finished dosage forms, from a single ISO 9001:2015 and GMP-certified manufacturing facility in Tarapur Industrial Estate, Maharashtra, near Mumbai and Nhava Sheva Port. Part of the Aarti Group of Industries, the company is diversifying beyond Paracetamol through its wholly-owned subsidiary Valiant Advanced Sciences Private Limited (VASPL), which is developing ketene and diketene-derivative specialty chemicals at a pilot plant.
Segments
- Paracetamol API
- Specialty Chemicals (VASPL)
- Manufacturing plants
- 1 (single-location facility, Tarapur Industrial Estate, Maharashtra)
- Installed Paracetamol capacity
- 900 MT/month (enhanced from 750 MT/month via equipment modifications, FY25)
- Permanent employees
- 79 (as on 31 March 2025)
- Specialty-chemical products under development (VASPL)
- 12+
- Paracetamol product grades
- 3 (Powder, Fine Powder, Crystals)
- Pharmacopoeia standards met
- 4 (IP, BP, USP, EP)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 4 fiscal years held (Mar 2023 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +421% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 35 | 58 | 51 | 46 | 55 | 65 | 73 |
| Expenses | 28 | 35 | 54 | 49 | 46 | 55 | 61 | 61 |
| Operating profit | -7 | 1 | 4 | 2 | 0 | 0 | 5 | 13 |
| Operating margin | −31.3% | 1.8% | 6.6% | 4.6% | 0.1% | 0.4% | 6.9% | 17.0% |
| Other income | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -5 | 1 | 4 | 2 | 0 | 0 | 5 | 13 |
| Tax rate | 12.4% | −122.2% | 17.6% | 25.7% | 34.6% | 80.0% | 25.3% | 25.6% |
| Net profit | -6 | 2 | 3 | 2 | 0 | 0 | 4 | 9 |
| EPS (₹ per share) | -1.10 | 0.29 | 0.60 | 0.34 | 0.03 | 0.01 | 0.65 | 1.75 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 182 | 133 | 217 |
| Expenses | 190 | 138 | 210 |
| Operating profit | -8 | -5 | 7 |
| Other income | 10 | 5 | 3 |
| Interest | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 |
| Profit before tax | -1 | -1 | 8 |
| Net profit | 0 | -2 | 6 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 16 | 33 | 43 | 43 | 54 | 54 |
| Reserves | 55 | 68 | 193 | 191 | 263 | 265 |
| Borrowings | 61 | 60 | 60 | 60 | 54 | 1 |
| Other liabilities | 49 | 52 | 28 | 23 | 54 | 65 |
| Total liabilities | 182 | 213 | 325 | 317 | 425 | 386 |
| Fixed assets | 22 | 30 | 32 | 30 | 48 | 30 |
| Capital work in progress | 1 | 0 | 0 | 0 | 174 | 0 |
| Investments | 0 | 34 | 119 | 165 | 48 | 191 |
| Other assets | 158 | 149 | 174 | 122 | 155 | 165 |
| Total assets | 182 | 213 | 325 | 317 | 425 | 386 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | 23 | 49 | -22 | -14 |
| Cash from investing | -21 | -183 | 25 | -8 |
| Cash from financing | -2 | 136 | 0 | 20 |
| Net cash flow | 0 | 2 | 3 | -2 |
| Free cash flow | 16 | 45 | -22 | -15 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 85 | 139 | 97 | 92 | 197 | 140 |
| Inventory days | 18 | 25 | 17 | 22 | 12 | 45 |
| Days payable | 37 | 72 | 62 | 54 | 61 | 118 |
| Cash conversion cycle | 66 | 91 | 52 | 60 | 149 | 67 |
| Working capital days | 102 | 109 | 106 | 97 | 194 | 158 |
| Return on capital employed | — | 38.0% | 26.0% | −2.0% | −1.0% | 2.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 74.94% as of Sept 2026; institutions added 0.15 pts since Jun 2026.
- Promoters 74.94%
- Foreign institutions 0.07%
- Domestic institutions 0.08%
- Public 24.91%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 1.87% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Valiant Laboratories Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 46.84% | unchanged | |
| 7.50% | unchanged | |
| 7.50% | unchanged | |
| 7.49% | −1.87 pp | |
| 3.72% | unchanged | |
| 1.87% | newly disclosed | |
| 1.84% | unchanged | |
| 0.02% | unchanged | |
| 0.01% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Valiant Laboratories Limited
Free account: one company. Everything above stays public.
Write why you follow Valiant Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Valiant Laboratories Limited
Guides on how to read this kind of business and the numbers that matter.